📊 CDLX Key Takeaways
Is Cardlytics, Inc. (CDLX) a Good Investment?
Cardlytics exhibits severe financial distress with negative stockholders' equity of -6.5M, indicating liabilities exceed assets. Despite 9.9% revenue growth, the company is deeply unprofitable with a -44.4% net margin and -101.8M operating loss, burning cash despite positive operating cash flow. The combination of negative equity, massive long-term debt of 212.6M, and inability to achieve profitability presents substantial solvency risk.
Cardlytics shows some fundamental improvement, with revenue growth near 10%, narrowing net losses, and modestly positive operating and free cash flow. However, the core business remains deeply unprofitable, leverage is heavy relative to its balance sheet, and negative equity signals a fragile financial position. Until sustained margin improvement and stronger balance sheet repair are evident, the fundamentals remain weak.
Why Buy Cardlytics, Inc. Stock? CDLX Key Strengths
- Revenue growth of 9.9% year-over-year demonstrates demand for services
- Positive operating cash flow of 9.3M and free cash flow of 8.8M provide near-term liquidity buffer
- Current ratio of 1.75x indicates adequate short-term liquidity to meet immediate obligations
- Revenue grew 9.9% year over year, indicating the business is still expanding
- Operating cash flow and free cash flow turned positive, supporting near-term liquidity
- Current and quick ratios of 1.75x suggest acceptable short-term liquidity despite losses
CDLX Stock Risks: Cardlytics, Inc. Investment Risks
- Negative stockholders' equity of -6.5M signals balance sheet insolvency and technical bankruptcy
- Operating margin of -43.6% and net margin of -44.4% indicate fundamental business model issues with losses on every dollar of revenue
- Long-term debt of 212.6M against only 285.6M total assets creates high leverage and refinancing risk, especially given inability to generate profits
- Net loss of 103.5M despite revenue growth demonstrates deteriorating operational performance regardless of top-line expansion
- Operating and net margins remain severely negative, showing the business model has not reached sustainable profitability
- Negative stockholders equity and $212.57M of long-term debt create significant balance sheet risk
- Negative interest coverage indicates earnings are insufficient to support debt costs
Key Metrics to Watch
- Path to operating profitability and improvement in operating margin trajectory
- Total liabilities relative to assets to monitor solvency and negative equity trend
- Operating cash flow sustainability and burn rate relative to cash reserves
- Operating margin trend and whether losses continue narrowing toward breakeven
- Cash balance versus debt obligations, including sustained positive operating cash flow
Cardlytics, Inc. (CDLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.8% FCF margin may limit capital allocation flexibility.
CDLX Profit Margin, ROE & Profitability Analysis
CDLX vs Technology Sector: How Cardlytics, Inc. Compares
How Cardlytics, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardlytics, Inc. Stock Overvalued? CDLX Valuation Analysis 2026
Based on fundamental analysis, Cardlytics, Inc. has mixed fundamental signals relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardlytics, Inc. Balance Sheet: CDLX Debt, Cash & Liquidity
CDLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cardlytics, Inc.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.69 indicates the company is currently unprofitable.
CDLX Revenue Growth, EPS Growth & YoY Performance
CDLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $47.0M | -$72.7M | $-1.36 |
| Q2 2025 | $58.0M | -$4.3M | $-0.09 |
| Q1 2025 | $56.4M | -$13.3M | $-0.26 |
| Q3 2024 | $61.1M | -$24.0M | $-0.63 |
| Q2 2024 | $64.0M | -$4.3M | $-0.09 |
| Q1 2024 | $59.0M | $13.6M | $0.40 |
| Q3 2023 | $67.3M | $6.3M | $0.19 |
| Q2 2023 | $69.3M | -$9.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cardlytics, Inc. Dividends, Buybacks & Capital Allocation
CDLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardlytics, Inc. (CIK: 0001666071)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDLX
What is the AI rating for CDLX?
Cardlytics, Inc. (CDLX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDLX's key strengths?
Claude: Revenue growth of 9.9% year-over-year demonstrates demand for services. Positive operating cash flow of 9.3M and free cash flow of 8.8M provide near-term liquidity buffer. ChatGPT: Revenue grew 9.9% year over year, indicating the business is still expanding. Operating cash flow and free cash flow turned positive, supporting near-term liquidity.
What are the risks of investing in CDLX?
Claude: Negative stockholders' equity of -6.5M signals balance sheet insolvency and technical bankruptcy. Operating margin of -43.6% and net margin of -44.4% indicate fundamental business model issues with losses on every dollar of revenue. ChatGPT: Operating and net margins remain severely negative, showing the business model has not reached sustainable profitability. Negative stockholders equity and $212.57M of long-term debt create significant balance sheet risk.
What is CDLX's revenue and growth?
Cardlytics, Inc. reported revenue of $233.3M.
Does CDLX pay dividends?
Cardlytics, Inc. does not currently pay dividends.
Where can I find CDLX SEC filings?
Official SEC filings for Cardlytics, Inc. (CIK: 0001666071) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDLX's EPS?
Cardlytics, Inc. has a diluted EPS of $-1.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CDLX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cardlytics, Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CDLX stock overvalued or undervalued?
Valuation metrics for CDLX: ROE of N/A (sector avg: 22%), net margin of -44.4% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy CDLX stock in 2026?
Our dual AI analysis gives Cardlytics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CDLX's free cash flow?
Cardlytics, Inc.'s operating cash flow is $9.3M, with capital expenditures of $480.0K. FCF margin is 3.8%.
How does CDLX compare to other Technology stocks?
Vs Technology sector averages: Net margin -44.4% (avg: 18%), ROE N/A (avg: 22%), current ratio 1.75 (avg: 2.5).